Tempest Therapeutics TPST Stock
Tempest Therapeutics Price Chart
Tempest Therapeutics TPST Financial and Trading Overview
| Tempest Therapeutics stock price | 0.71 USD |
| Previous Close | 1.41 USD |
| Open | 1.5 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.36 - 1.5 USD |
| 52 Week Range | 1.06 - 4.21 USD |
| Volume | 34.87K USD |
| Avg. Volume | 266.28K USD |
| Market Cap | 16.45M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19 USD |
TPST Valuation Measures
| Enterprise Value | 15.07M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.6454545 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3680154 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.451 |
Trading Information
Tempest Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -31.73% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.21 USD |
| 52 Week Low | 1.06 USD |
| 50-Day Moving Average | 2.07 USD |
| 200-Day Moving Average | 1.82 USD |
TPST Share Statistics
| Avg. Volume (3 month) | 266.28K USD |
| Avg. Daily Volume (10-Days) | 97.25K USD |
| Shares Outstanding | 11.59M |
| Float | 3.86M |
| Short Ratio | 0.33 |
| % Held by Insiders | 3.23% |
| % Held by Institutions | 69.71% |
| Shares Short | 39.92K |
| Short % of Float | 0.55% |
| Short % of Shares Outstanding | 0.33% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.82% |
| Return on Equity (ttm) | -172.87% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -33405000 USD |
| Net Income Avi to Common (ttm) | -34854000 USD |
| Diluted EPS (ttm) | -2.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 22.93M USD |
| Total Cash Per Share (mrq) | 1.98 USD |
| Total Debt (mrq) | 21.66M USD |
| Total Debt/Equity (mrq) | 197.53 USD |
| Current Ratio (mrq) | 3.285 |
| Book Value Per Share (mrq) | 1.038 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -32268000 USD |
| Levered Free Cash Flow (ttm) | -20006624 USD |
Profile of Tempest Therapeutics
| Country | United States |
| State | CA |
| City | Brisbane |
| Address | 2000 Sierra Point Parkway |
| ZIP | 94005 |
| Phone | 415 798 8589 |
| Website | https://www.tempesttx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Q&A For Tempest Therapeutics Stock
What is a current TPST stock price?
Tempest Therapeutics TPST stock price today per share is 0.71 USD.
How to purchase Tempest Therapeutics stock?
You can buy TPST shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tempest Therapeutics?
The stock symbol or ticker of Tempest Therapeutics is TPST.
Which industry does the Tempest Therapeutics company belong to?
The Tempest Therapeutics industry is Biotechnology.
How many shares does Tempest Therapeutics have in circulation?
The max supply of Tempest Therapeutics shares is 43.64M.
What is Tempest Therapeutics Price to Earnings Ratio (PE Ratio)?
Tempest Therapeutics PE Ratio is now.
What was Tempest Therapeutics earnings per share over the trailing 12 months (TTM)?
Tempest Therapeutics EPS is -1.5 USD over the trailing 12 months.
Which sector does the Tempest Therapeutics company belong to?
The Tempest Therapeutics sector is Healthcare.
Tempest Therapeutics TPST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17449.89 USD — |
+0.87
|
6.97B USD — | 17149.36 USD — | 17506.58 USD — | — - | 6.97B USD — |
| NASDAQ HealthCare IXHC | 929.13 USD — |
-1.85
|
— — | 925.14 USD — | 947.12 USD — | — - | — — |
- {{ link.label }} {{link}}